Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A

2(40.0%)

Phase 4

2(40.0%)

Phase 3

1(20.0%)

5Total

N/A(2)

Phase 4(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT04767204Not ApplicableCompleted

The Outcomes Among Persons With Schizophrenia Under the Peer-support Service in Vocational Rehabilitation Program

Role: lead

NCT00797277Phase 3Completed

Intramuscular (IM) Olanzapine Versus IM Haloperidol Plus Lorazepam for Acute Agitation in Schizophrenia

Role: collaborator

NCT00956189Not ApplicableCompleted

Identification and Treatment Response Prediction of Antipsychotic-Related Metabolic Syndrome

Role: collaborator

NCT00495352Phase 4Completed

The Pharmacogenetic Study , Readiness to Change, and Pharmacological Intervention for Smoking Cessation in Schizophrenia

Role: lead

NCT00468533Phase 4Unknown

The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole Trial

Role: lead

All 5 trials loaded